Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality

The literature review on 5α-reductase inhibitors (5-ARIs) highlights their potential therapeutic benefits in managing prostate cancer but also raises significant concerns about their safety, particularly their association with high-grade tumors and implications for mortality. The conclusion emphasizes the need for a cautious and informed approach in clinical practice, advocating for future research to better understand the complexities of 5-ARIs and their integration with existing treatment protocols, with a focus on individualized patient care.